Sperl, Jan <br/><br/>
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.  [electronic resource] 

 -  Kidney & blood pressure research  2018 
 - 594-605 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1423-0143 
<br/><br/><label>Standard No.: </label>10.1159/000488965  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Anilides--therapeutic use<br/>Antihypertensive Agents--therapeutic use<br/>Antiviral Agents--adverse effects<br/>Carbamates--therapeutic use<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Kidney Failure, Chronic--therapy<br/>Lactams, Macrocyclic<br/>Macrocyclic Compounds--therapeutic use<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Renal Insufficiency--therapy<br/>Ritonavir--therapeutic use<br/>Sulfonamides--therapeutic use<br/>Treatment Outcome<br/>Uracil--analogs & derivatives<br/>Valine